242 related articles for article (PubMed ID: 21188213)
21. Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Scheel AH; Penault-Llorca F; Hanna W; Baretton G; Middel P; Burchhardt J; Hofmann M; Jasani B; Rüschoff J
Diagn Pathol; 2018 Mar; 13(1):19. PubMed ID: 29530054
[TBL] [Abstract][Full Text] [Related]
22. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
[TBL] [Abstract][Full Text] [Related]
23. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
24. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer.
Kahraman S; Yalcin S
Onco Targets Ther; 2021; 14():4149-4162. PubMed ID: 34285507
[TBL] [Abstract][Full Text] [Related]
26. [ISH-based HER2 diagnostics].
Rüschoff J; Nagelmeier I; Jasani B; Stoss O
Pathologe; 2020 Nov; 41(6):606-613. PubMed ID: 33001242
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
Song Y; Huang J; Wang JW
Chin J Cancer; 2010 Jan; 29(1):76-81. PubMed ID: 20038314
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
[TBL] [Abstract][Full Text] [Related]
29. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.
Zhang XL; Yang YS; Xu DP; Qu JH; Guo MZ; Gong Y; Huang J
World J Surg; 2009 Oct; 33(10):2112-8. PubMed ID: 19636613
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
31. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
[TBL] [Abstract][Full Text] [Related]
33. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
34. Chromogenic
Ali AHM; Yahya AQ; Mohammed HL
Open Access Maced J Med Sci; 2019 Jun; 7(12):1917-1925. PubMed ID: 31406529
[TBL] [Abstract][Full Text] [Related]
35. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Al-Batran SE; Moorahrend E; Maintz C; Goetze TO; Hempel D; Thuss-Patience P; Gaillard VE; Hegewisch-Becker S
Oncologist; 2020 Aug; 25(8):e1181-e1187. PubMed ID: 32311799
[TBL] [Abstract][Full Text] [Related]
36. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.
Schlüter B; Gerhards R; Strumberg D; Voigtmann R
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1389-400. PubMed ID: 20217132
[TBL] [Abstract][Full Text] [Related]
37. Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.
Huemer F; Weiss L; Regitnig P; Winder T; Hartmann B; Thaler J; Piringer G; Schmitt CA; Eisterer W; Gänzer H; Wüstner A; Andel J; Jagdt B; Ulmer H; Greil R; Wöll E
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32235305
[TBL] [Abstract][Full Text] [Related]
38. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
39. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
40. Targeting the human epidermal growth factor receptor 2 in esophageal cancer.
Almhanna K; Meredith KL; Hoffe SE; Shridhar R; Coppola D
Cancer Control; 2013 Apr; 20(2):111-6. PubMed ID: 23571701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
